Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lefamulin Acetate

            Therapeutic Area: Infections and Infectious Diseases Product Name: Xenleta

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Nabriva Therapeutics

            Deal Size: $101.0 million Upfront Cash: $5.0 million

            Deal Type: Licensing Agreement December 07, 2020

            Details:

            The restructured agreement provides for additional manufacturing collaboration and regulatory support [to be provided to Sinovant by Nabriva] that is expected to help expedite the delivery of XENLETA to patients in greater China.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lefamulin Acetate

            Therapeutic Area: Infections and Infectious Diseases Product Name: Xenleta

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 13, 2020

            Details:

            Findings underscore potential of XENLETA as a first-in-class pleuromutilin antibiotic for the IV and oral treatment of CABP in adults, including older patients with comorbidities who are at risk of poor outcomes

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lefamulin Acetate

            Therapeutic Area: Infections and Infectious Diseases Product Name: Xenleta

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 23, 2020

            Details:

            In pre-clinical model, lefamulin shows anti-inflammatory activity comparable to dexamethasone.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lefamulin Acetate

            Therapeutic Area: Infections and Infectious Diseases Product Name: Xenleta

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 16, 2020

            Details:

            Nabriva Therapeutics has received approval from Health Canada to market oral and intravenous (IV) formulations of XENLETA® (lefamulin) for the treatment of community-acquired pneumonia (CAP) in adults.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tedizolid Phosphate

            Therapeutic Area: Infections and Infectious Diseases Product Name: Sivextro

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Merck & Co. Inc.

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement July 15, 2020

            Details:

            Under the terms of the agreement, Nabriva will procure SIVEXTRO from Merck & Co. Inc., Kenilworth, N.J., USA and be responsible for marketing, sales, and distribution of SIVEXTRO in the U.S. through December 31, 2023, with renewable three-year extensions.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lefamulin Acetate

            Therapeutic Area: Infections and Infectious Diseases Product Name: Xenleta

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: WEP

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership July 06, 2020

            Details:

            Under the terms of the NPP, XENLETA will be made available in 2 formulations - 150mg injection for IV administration and 600mg oral tablets - using named patient or expanded access managed by WEP to enable healthcare professionals to access XENLETA to meet clinical needs.